BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Exicure Signs MOU to Acquire GPCR USA and Advance Collaborative Research in Drug Development

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...

December 30, 2024 | News

Alphamab Oncology Receives NMPA Approval for Phase I/II Trial of Groundbreaking Subcutaneous Co-Formulation JSKN033

Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co...

December 27, 2024 | News

Taiwan’s Taikang Biotech Joins Forces with Mitsubishi Gas Chemical and Taiwan Sugar Alliance to Propel SPD8 Biosimilar Globally

Taikang Biotech (6589), Mitsubishi Gas Chemical Co., Ltd. (MGC), and the Taiwan Sugar Association (4168) have entered into a strategic tripartite agreement...

December 26, 2024 | News

Axcelead Drug Discovery Partners Joins Forces with Astellas Pharma to Advance Targeted Protein Degrader Research

Axcelead Drug Discovery Partners, Inc. announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Ch...

December 26, 2024 | News

Keymed Biosciences Secures NMPA Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyposis

Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New D...

December 24, 2024 | News

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Vertex Announces FDA Approval of ALYFTREK™: A Once-Daily CFTR Modulator for Cystic Fibrosis Patients Aged 6 and Older

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not re...

December 23, 2024 | News

CStone Pharmaceuticals Submits Clinical Trial Application in Australia for CS2009, a Tri-Specific Antibody Targeting Solid Tumors

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

December 23, 2024 | News

SCG Cell Therapy Partners with A*STAR BTI and NATi to Accelerate RNA-Based Therapeutics Development and Commercialization

SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Ini...

December 23, 2024 | News

Sanofi Acquires Greater China Rights for Aficamten from CORXEL, Expanding HCM Treatment Reach

Cytokinetics, Incorporated announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL...

December 20, 2024 | News

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...

December 20, 2024 | News

Merck Accelerates Next-Generation Drug Discovery with Acquisition of HUB Organoids

HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fas...

December 19, 2024 | News

Everest Medicines’ VELSIPITY® Prescribed in Mainland China, Pioneering New Ulcerative Colitis Treatment under Hong Kong-Macau Connect

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

December 18, 2024 | News

25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine

Biopharma in 2025: AI Transforming Drug Discovery and Precision Medicine The biopharma landscape in 2025 is poised for an unprecedented transformation, dr...

December 13, 2024 | Analysis

Stay Connected